Simon Campbell is a synthetic organic chemist who received his PhD from the University of Birmingham in 1965 followed by postdoctoral appointments in Chile and Stanford. From 1969 to 1972, he was Visiting Professor at the Universidade do Sao Paulo in Brazil, and then returned to the UK to join Pfizer Central Research in Sandwich. Dr Campbell retired from Pfizer in 1998 as Senior Vice President for Worldwide Discovery and Medicinals R&D Europe. He has co-authored over 120 publications and patents, and was a key member of the research teams that discovered Cardura™, Norvasc™, and Viagra™.
Dr Campbell’s scientific contributions have been recognised by the RSC Award for Medicinal Chemistry (1989), the Herschberg Award from the American Chemical Society (1997), the Industrial Research Institute (US) Achievement Award (1997), the CIA Individual Achievement Award (2006), Galen Medal (2007) and the Sir James Black Award for Drug Discovery (2012). He was elected FRS (1999), FMedSci (2002) and was appointed CBE in 2006 for “Services to Science” followed by a knighthood in 2015 for “Services to Chemistry”. Dr Campbell was named at number 31 in the Times Eureka list of 100 top UK scientists for 2010, and was included in the Science Council list of the UK’s 100 practising scientists in 2014.
Currently, Dr. Campbell is a member of the SABs of Astex (Cambridge), Bionomics (Adelaide) Calibr (San Diego) CTx (Melbourne) Ensemble (Boston), H3-D (Cape Town), Kura (San Diego), MRCT (London) and the TB Alliance (Seattle). He acts as a consultant to Abingworth Management, Apposite Capital, CRUK, DNDi, MMV Novo Seeds and the Wellcome Trust, and has worked with CNPq/FAPESP in Brazil. He is a past President of the RSC and has served on the RS Council, and was the first chair of the Expert Scientific Advisory Committee for the Medicines for Malaria Venture